The perturbation of apoptosis and mitosis by drugs and xenobiotics.

Drugs such as the barbiturate phenobarbitone and fibrate hypolipidaemic agents, in addition to a range of chemicals of environmental and industrial significance, are able to perturb rodent tissue homeostasis, leading to tissue enlargement. Many of these xenobiotics are rodent nongenotoxic carcinogens since they do not damage DNA, yet cause tumours in the rat and mouse. These nongenotoxic carcinogens display both species and tissue specificity; for example, rat and mouse hepatocytes display S-phase induction and a suppression of apoptosis in response to drugs such as phenobarbitone or the hypolipidaemic peroxisome proliferators (PPs). In contrast, human hepatocytes or other types of rodent cells are refractory to these effects. However, in the absence of a discrete mechanism of action, the clear species differences preclude extrapolation of rodent data to provide an accurate human risk assessment. Recent data have demonstrated that PPs activate the PP-activated receptor alpha in rodent liver, leading to enzyme induction, stimulation of S-phase, and a suppression of apoptosis. How these acute effects may lead to hepatocarcinogenesis and the relevance of this for humans will be discussed.

[1]  G. Williams,et al.  Mechanism‐based Risk Assessment of Peroxisome Proliferating Rodent Hepatocarcinogens , 1996, Annals of the New York Academy of Sciences.

[2]  N. Macdonald,et al.  Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). , 1998, Carcinogenesis.

[3]  G. Evan,et al.  Apoptosis and the cell cycle. , 1995, Current opinion in cell biology.

[4]  M. Rolfe,et al.  Tumour necrosis factor alpha (TNF alpha) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators? , 1997, Carcinogenesis.

[5]  S. Green.  The search for molecular mechanisms of non-genotoxic carcinogens. , 1991, Mutation research.

[6]  E. Wheeldon,et al.  Quantitation of Apoptotic Bodies in Rat Liver by In Situ End Labelling (ISEL): Correlation with Morphology , 1995, Toxicologic pathology.

[7]  W. Bursch,et al.  Effect of transforming growth factor beta on cell death of cultured rat hepatocytes. , 1991, Cancer research.

[8]  R. Roberts.  Non‐genotoxic Hepatocarcinogenesis: Suppression of Apoptosis by Peroxisome Proliferators , 1996, Annals of the New York Academy of Sciences.

[9]  J. Berman,et al.  Comparison of the effects of the hypolipidaemic agents ICI 53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat , 1983, British journal of pharmacology.

[10]  M. Raff,et al.  Programmed Cell Death in Animal Development , 1997, Cell.

[11]  S. Nagata,et al.  Fas-mediated apoptosis in primary cultured mouse hepatocytes. , 1994, Experimental cell research.

[12]  C. Dive,et al.  Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin , 1994, The Journal of cell biology.

[13]  R. Schlegel,et al.  Apoptosis and the cell cycle , 1995, Journal of cellular biochemistry.

[14]  E. Staffeldt,et al.  Comparative enhancing effects of phenobarbital, amobarbital, diphenylhydantoin, and dichlorodiphenyltrichloroethane on 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. , 1975, Cancer research.

[15]  Yamada Junji,et al.  Species differences in the effects of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes. , 1989 .

[16]  R. Roberts,et al.  Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. , 1996, Carcinogenesis.

[17]  G. Gibson,et al.  Immunochemical study on the contribution of hypolipidaemic-induced cytochrome P-452 to the metabolism of lauric acid and arachidonic acid. , 1985, Biochemical pharmacology.

[18]  W. Bursch,et al.  Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate , 1986, Archives of Toxicology.

[19]  R. Roberts,et al.  A peroxisome proliferator-activated receptor-alpha (PPARα) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARα: implications for species differences in responses to peroxisome proliferators , 1998, Archives of Toxicology.

[20]  A. Columbano,et al.  Effects of cell proliferation and cell death (apoptosis and necrosis) on the early stages of rat hepatocarcinogenesis. , 1996, Carcinogenesis.

[21]  P. Eacho,et al.  Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. , 1986, Toxicology and applied pharmacology.

[22]  C Kemmer,et al.  Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. , 1983, Atherosclerosis.

[23]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[24]  E. Wheeldon,et al.  Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. , 1995, Carcinogenesis.

[25]  B. Lake,et al.  Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. , 1989, Toxicology and applied pharmacology.

[26]  P Grasso,et al.  Hepatic peroxisome proliferation in rodents and its significance for humans. , 1993, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[27]  R. Heller,et al.  Tumor necrosis factor receptor-mediated signaling pathways , 1994, The Journal of cell biology.

[28]  M. Rao,et al.  Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin , 1977, Virchows Archiv. B, Cell pathology.

[29]  C. Elcombe,et al.  Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): species differences and possible mechanisms. , 1986, Environmental health perspectives.

[30]  B. Lake,et al.  Peroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[31]  P. Eacho,et al.  Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. , 1990, Toxicology and applied pharmacology.

[32]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[33]  J. Reddy,et al.  Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. , 1979, Cancer research.

[34]  W. Bursch,et al.  Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. , 1984, Carcinogenesis.

[35]  B. Lake.  Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. , 1995, Annual review of pharmacology and toxicology.

[36]  Michael Karin,et al.  Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.

[37]  R. J. Price,et al.  Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and Syrian hamster. , 1992, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[38]  G. Cohen,et al.  Apoptosis and necrosis in toxicology: a continuum or distinct modes of cell death? , 1997, Pharmacology & therapeutics.

[39]  M. Leist,et al.  ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. , 1997, Immunology letters.

[40]  W. Bursch,et al.  Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. , 1990, Carcinogenesis.

[41]  N. Macdonald,et al.  Amino acid residues in both the DNA-binding and ligand-binding domains influence transcriptional activity of the human peroxisome proliferator-activated receptor alpha. , 1997, Biochemical and biophysical research communications.

[42]  J. Reddy,et al.  Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens , 1980, Nature.

[43]  R. Schulte‐Hermann,et al.  Adaptive responses of rat liver to the gestagen and anti-androgen cyproterone acetate and other inducers. II. Induction of growth. , 1980, Chemico-biological interactions.

[44]  M. Virji,et al.  Modulation of epidermal growth factor receptors in rat hepatocytes by two liver tumor-promoting regimens, a choline-deficient and a phenobarbital diet. , 1988, Cancer research.

[45]  S Kettle,et al.  Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis , 1994, Human & experimental toxicology.

[46]  A. Edwards,et al.  Phenobarbital and some other liver tumor promoters stimulate DNA synthesis in cultured rat hepatocytes. , 1985, Biochemical and biophysical research communications.

[47]  A. Columbano,et al.  Cell proliferation and promotion of rat liver carcinogenesis: different effect of hepatic regeneration and mitogen induced hyperplasia on the development of enzyme-altered foci. , 1990, Carcinogenesis.

[48]  J. Bar-Tana,et al.  Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. , 1995, The Journal of Biological Chemistry.

[49]  H. K. Bojes,et al.  Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. , 1997, Carcinogenesis.

[50]  A. Chinnaiyan,et al.  FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis (*) , 1996, The Journal of Biological Chemistry.

[51]  A. Whetton,et al.  Induction of apoptosis--new targets for cancer chemotherapy. , 1992, Seminars in cancer biology.